P eriprosthetic joint infection (PJI)
remains a daunting problem that is costly both in terms of health economics and harm to patients. Proprionobacterium acnes (P. acnes) now causes about 40% shoulder PJIs, probably because it appears in such high concentration in the skin of the upper extremity [2] . These infections can be challenging to diagnose because P. acnes grows slowly and can be difficult to recover in culture. In addition, positive cultures can be found in patients who are not suspected of an infection, making it difficult to distinguish among contamination, commensal presence, or true infection.
Other biofilm-producing organisms pose a similar challenge in that their planktonic concentration in synovial fluid may defy detection using conventional sampling and culture techniques. Thus, joint aspiration may yield a high percentage of false-negative results. Conventional blood markers of inflammation may also be normal in such infections, which are generally diagnosed by tissue cultures when other diagnostic tests and treatment options have failed. The preponderance of such indolent infections following shoulder arthroplasty make it difficult to apply the American Academy of Orthopaedic Surgeons Clinical Practice Guidelines for knee and hip arthroplasty [4] . No such guideline has yet been established specifically for shoulder PJI.
Such challenges equally make it difficult to define what constitutes a cure when it comes to treatment for shoulder PJI. In the current study, Grubhofer and colleagues reported a high rate of infection controls with staged treatment of infected total shoulders using an interim antibiotic spacer. Their series included a variety of different definitive treatment options depending on the degree of bone loss at the time of reimplantation. This highlights the difficulty of relying on clinical and radiological data to define successful eradication of PJI, particularly given the spectrum of reconstructive methods and functional outcomes. Spacer retention and revision to hemiarthroplasty may have a "limited goals" outcome with persistent discomfort and loss of function making outcome data an uncertain surrogate for infection control.
Where Do We Need To Go?
We still need better detection and treatment options for PJI, particularly in cases of indolent bacteria. Because P. acnes resides in the dermis, conventional skin preparation solutions may be ineffective in preventing wound contamination at the time of surgical incision. While dilute betadine lavage at the time of closure has reduced PJI, these treatment options have not achieved consensus as standard of care [3] . The same is true for the addition of vancomycin powder into the surgical wound which has gained some traction in spinal surgery [6] . Further high-quality clinical studies are needed to define the value of such strategies in reducing wound contamination and PJI. Biomarkers such as alpha defensin show promise in increasing the sensitivity of PJI detection, but little is yet known about the potential falsenegative rates for organisms that may be too difficult to detect by other means [7] . Continued efforts in this area will greatly impact our ability to diagnose PJI in patients where it is suspected based on the clinical presentation of pain or prosthesis loosening.
Molecular techniques such as polymerase chain reaction have also been shown to improve detection of PJI when used in combination with prosthesis sonication to remove biofilm material [1] . Like bioassays, these methods are not widely available, nor have criteria been established by which to routinely employ these methods in clinical practice. Further research in this area offers great hope provided that these methods are supported by robust sampling guidelines.
How Do We Get There?
The intersection of biomedical engineering with clinical practice and surgical care has the potential to advance scientific discovery and technology. One such area of focus is the use of implantable sensors, which are currently in use for joint replacement for force and motion analysis. Sensors like Synotrac (DEF Medical Technologies, Philadelphia, PA, USA) can similarly be used to measure the body's immune response during the healing process and can proactively alert patients and physicians to changes in the joint's biological environment that are consistent with infection. While this technology is in its infancy, the pervasion of microchip technology in other areas of science and medicine will likely progress, particularly in joint replacement.
Further opportunities exist in the field of materials science. Research into bioactive coatings suggests that certain surface coating compounds may possess bacteriostatic properties that may be infection resistant by preventing the formation of biofilms [5] . If this technology can be combined with consensus guidelines on reducing bacterial contamination of the surgical field, then the incidence of PJI can hopefully be substantially reduced.
Clinical studies that evaluate the best sampling and culture techniques to improve the yield and accuracy of diagnosing PJI is critical, particularly for indolent bacteria, where classic signs of infection may be absent. Some of this information will come from laboratory scientific investigation looking into ways of improving culture and defining proper incubation times. Clinical trials are also necessary to determine the number of samples, type and location of tissue, and method of procurement. Given the aim to reduce the frequency of PJI, powering such studies and randomizing patients to specific sampling techniques would be extremely difficult. Similarly, establishing a control group can be challenging given that some of these bacteria seem to defy detection. Still, establishing sampling methods that reduce the likelihood of contamination and maximize yields could potentially reduce the variability in our methods and allow for better meta-analyses of case series.
Future clinical trials are also necessary to validate the role of intrawound antibiotic powder and dilute betadine lavage as standard practice techniques in reducing PJI. Although the research is promising, we still need high-quality data to determine if wound decontamination using betadine and antibiotics merits evidence-based practice.
